Division of Life Sciences and Medicine, Cancer Research Center, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
International Cooperation Laboratory on Signal Transduction, Ministry of Education Key Laboratory on Signaling Regulation and Targeting Therapy of Liver Cancer, Shanghai Key Laboratory of Hepato-biliary Tumor Biology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Front Immunol. 2020 Mar 12;11:339. doi: 10.3389/fimmu.2020.00339. eCollection 2020.
Immune checkpoint inhibitors target the inhibitory receptors on T cells to reinstate their antitumor ability and have shown significant efficacy in treating various cancers. However, because of tumor heterogeneity and many other uncover reasons, the objective response rate for programmed death 1 and programmed death-ligand 1 (PD-1/PD-L1) blockade is only 20 to 30%; its response rate in solid tumors is relatively low, and different degrees of side effects have occurred. There are still many unknown factors affecting the therapeutic effectiveness of PD-1/PD-L1 blockade. Additionally, screening the responding tumor patients accurately and improving the response rate and efficacy are huge challenges for tumor precise treatment. Here, we attempt to summarize the recent progress in response prediction and combined application of PD-1/PD-L1 blockade and briefly discuss the methods and evaluations combined with PD-1/PD-L1 blockade to improve the implementation of precision immunotherapy.
免疫检查点抑制剂针对 T 细胞上的抑制性受体，重新激活其抗肿瘤能力，在治疗各种癌症方面显示出显著疗效。然而，由于肿瘤异质性和许多其他未知原因，程序性死亡 1 和程序性死亡配体 1（PD-1/PD-L1）阻断的客观反应率仅为 20%至 30%；其在实体肿瘤中的反应率相对较低，并且发生了不同程度的副作用。仍有许多未知因素影响 PD-1/PD-L1 阻断的治疗效果。此外，准确筛选对 PD-1/PD-L1 阻断有反应的肿瘤患者，提高反应率和疗效，是肿瘤精准治疗的巨大挑战。在这里，我们尝试总结 PD-1/PD-L1 阻断的反应预测和联合应用的最新进展，并简要讨论结合 PD-1/PD-L1 阻断改善精准免疫治疗实施的方法和评估。
